NCT02595736View on ClinicalTrials.gov

A Study of LY3200327 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Healthy
Interventions
DRUG

Placebo (SC)

Administered SC

DRUG

LY3200327 (SC)

Administered SC

DRUG

LY3200327 (IV)

Administered IV

DRUG

Placebo (IV)

Administered IV

Trial Locations (1)

91206

Parexel International/ California Clinical Trials, Glendale

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02595736 - A Study of LY3200327 in Healthy Participants | Biotech Hunter | Biotech Hunter